



## Final Appraisal Recommendation

Advice No: 1718 – October 2018

### Conestat alfa (Ruconest<sup>®</sup>) 2100 U powder and solvent for solution for injection, 2100 U powder for solution for injection

#### Submission by Pharming Group N.V

#### Recommendation of AWMSG

**Conestat alfa (Ruconest<sup>®</sup>) is recommended as an option for use within NHS Wales for the treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema due to C1 esterase inhibitor deficiency.**

**This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.**

#### Additional note(s):

- AWMSG considered that conestat alfa (Ruconest<sup>®</sup>) satisfied the AWMSG criteria for an ultra-orphan equivalent medicine.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 786), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1718:  
Conestat alfa (Ruconest<sup>®</sup>) 2100 U powder and solvent for solution for injection, 2100 U powder for solution for injection. October 2018